![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
API Suppliers
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
USA (Orange Book)
Europe
0
Canada
Australia
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
Annual Reports
0
0
https://www.ema.europa.eu/en/documents/overview/tepmetko-epar-medicine-overview_en.pdf
https://www.pharmatimes.com/news/mhra_backs_mercks_met_inhibitor_tepmetko_1380739
https://www.globenewswire.com/news-release/2021/08/17/2281638/0/en/AmoyDx-Pan-Lung-Cancer-PCR-Panel-Receives-MHLW-Approval-as-Companion-Diagnostic-for-TEPMETKO-tepotinib.html
http://www.pharmatimes.com/news/mercks_met_inhibitor_tepotinib_gains_positive_opinion_from_mhra_1373134
https://www.prnewswire.com/news-releases/fda-approves-tepmetko-as-the-first-and-only-once-daily-oral-met-inhibitor-for-patients-with-metastatic-nsclc-with-metex14-skipping-alterations-301221542.html
https://www.prnewswire.com/news-releases/fda-approves-tepmetko-as-the-first-and-only-once-daily-oral-met-inhibitor-for-patients-with-metastatic-nsclc-with-metex14-skipping-alterations-301221542.html
http://www.pharmatimes.com/news/eu_to_review_mercks_targeted_lung_cancer_drug_1358459
https://www.pharmiweb.com/press-release/2020-11-27/european-medicines-agency-validates-application-for-tepotinib-for-the-treatment-of-advanced-nsclc-wi
https://pharmaphorum.com/news/fda-starts-quick-review-of-mercks-met-targeting-lung-cancer-drug/
https://www.prnewswire.com/news-releases/fda-accepts-filing-of-new-drug-application-for-tepotinib-for-the-treatment-of-patients-with-metastatic-nsclc-with-metex14-skipping-alterations-301117906.html
http://www.pmlive.com/pharma_news/novartis_pulls_ahead_of_merck_in_met-positive_lung_cancer_race_1325056
https://www.biospectrumasia.com/news/34/14964/merck-presented-data-on-tepotinib-for-nsclc-at-esmo-asia-2019.html
https://www.biospace.com/article/releases/merck-kgaa-darmstadt-germany-announces-orphan-drug-designation-for-investigational-therapy-tepotinib-in-patients-with-nsclc-harboring-met-gene-alterations/?s=95
https://endpts.com/merck-kgaa-touts-fda-breakthrough-status-blockbuster-potential-in-bid-to-investors/
https://endpts.com/asco19-met-inhibitors-from-incyte-novartis-and-germanys-merck-face-off-for-rare-subset-of-nsclc-patients/
https://www.prnewswire.com/news-releases/merck-kgaa-darmstadt-germany-provides-update-on-tepotinib-phase-ii-results-in-advanced-hepatocellular-carcinoma-685120081.html